1248 Management LLC Takes Position in Sanofi $SNY

Key Points

• 1248 Management LLC has acquired a new stake in Sanofi, purchasing 7,054 shares valued at approximately $391,000 in the first quarter of 2023.
• Several other investors have also made moves with Sanofi shares, including Accent Capital Management and Eastern Bank, which increased their holdings significantly during the same period.
• Analysts have mixed ratings on Sanofi, with a consensus rating of "Buy" and a price target of $62.00, while recent earnings showed a miss on EPS expectations.

1248 Management LLC bought a new position in shares of Sanofi (NASDAQ:SNY - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,054 shares of the company's stock, valued at approximately $391,000.

A number of other institutional investors also recently bought and sold shares of SNY. Brighton Jones LLC boosted its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Sanofi by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 164,538 shares of the company's stock worth $7,936,000 after purchasing an additional 5,198 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Sanofi by 33.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,174 shares of the company's stock worth $153,000 after purchasing an additional 792 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Sanofi by 122.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 356,058 shares of the company's stock worth $17,180,000 after purchasing an additional 195,719 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Sanofi by 44.9% during the fourth quarter. Northern Trust Corp now owns 1,930,560 shares of the company's stock worth $93,111,000 after purchasing an additional 597,959 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Finally, Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $62.00.

Sanofi Stock Performance

Shares of NASDAQ SNY traded down $4.56 during mid-day trading on Thursday, hitting $45.33. The company had a trading volume of 8,958,640 shares, compared to its average volume of 2,575,112. The stock has a market cap of $111.31 billion, a price-to-earnings ratio of 10.90, a PEG ratio of 1.18 and a beta of 0.51. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The firm's 50 day simple moving average is $48.90 and its two-hundred day simple moving average is $51.51.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company's revenue for the quarter was down 7.0% on a year-over-year basis. During the same period last year, the business posted $1.73 EPS. As a group, equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.